Evelyn Warner, Author at Labiotech.eu

About

Ex-Editor. Recovering organic chemist. Chagrined member of the Brooklyn-Berlin exchange program. Proud parent of a majestic domestic long hair.

Articles by Evelyn Warner

News and Trends 20 Aug 2016

France is loving this Iranian Bioartist’s Microbe-Inspired Installations

Bioartist Golnaz Behrouznia creates gorgeous multimedia installations inspired by microscopic life. Keep an eye out for her work at festivals in Paris and Toulouse this September. Golnaz Behrouznia has always been passionate about natural science, particularly the world seen through a microscope. Through a combination of plastic sculpture, drawing, and installation video, she brings it […]

August 20, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 18 Aug 2016

Invidior approaches FDA Approval of Opioid Addiction Treatment

Invidior has revamped buprenorphine with a sustained release formulation known as RBP-6000 that shows promising results in Phase III clinical trials for the treatment of opioid addiction. The latest addiction treatment from Invidior, RBP-6000, has made considerable progress through Phase III clinical trials. At the core of RBP-6000 is the old drug, buprenorphine, but Invidior has […]

August 18, 2016 - 3 minutesmins - By Evelyn Warner

synthetic biology bioelectronics igem living lightbulb

News and Trends 17 Aug 2016

Illuminating Synthetic Biology: Undergraduate team develops a bioelectric lightbulb

A group of undergraduate researchers at Newcastle University has created a lightbulb from genetically engineered E. coli. In the pipeline are also a hybridised batteries, a capacitor, and a resistor, and the forthcoming circuit will serve as the team’s entry into 2016’s iGEM competition. We’ve heard of fungi furniture, but synthetic biology is extending tendrils into another area of interior design: […]

August 17, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 9 May 2016

Update: Cold Sore Season is Here! AiCuris might have a Herpes Cure

Update (09/05/2017): AiCuris has started a Phase II trial, PRIOH-1, with the oral version of its herpes cure pritelivir. Update (17/01/2017): The company has presented results from its first Phase II trial with pritelivir. The drug candidate proved to work better than the antiviral drug valacyclovir, currently the standard of care. Update (01/12/2017): AiCuris announced […]

May 9, 2016 - 2 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us